March 25, 2021 05:24 AM EDTUpdated March 30, 05:15 AM
Financing
Startups

Neu­ro up­start launch­es out of RA Cap­i­tal’s low-pro­file in­cu­ba­tor with Big Phar­ma vets, clin­i­cal drugs and $80M

Amber Tong

Senior Editor

As a pain re­searcher of 20-plus years, Va­lerie Moris­set doesn’t get ex­cit­ed about new drug ideas eas­i­ly.

So when An­drew Levin from RA Cap­i­tal called …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times